Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Strong dollar plus strong franc equals worries for global Big Pharma

When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.

J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula

Johnson & Johnson's antipsychotic med Invega Sustenna is already bringing in blockbuster-plus sales for J&J, and if the company has its way, a new, even longer acting formula will give the franchise an even bigger boost.

J&J faces sales, currency headwinds abroad in 2015

Johnson & Johnson was strongly hit by weaker currencies across Asia in the fourth quarter with the company struggling to hedge risk, indicating to executives that further impacts to the bottom line in these fast-growing markets are expected in 2015.

J&J and Takeda open up an Israeli biotech incubator

Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation.

Medical devices weigh on J&J; focuses on innovation, hospital bundling to improve

Johnson & Johnson is working to make its medical device business grow as fast as the pharmaceutical side--but for now devices sales growth is slowing, while pharma is picking up fast. 

J&J's pharma unit 'fastest-growing' in the drug business, CEO Gorsky says

Johnson & Johnson's new drugs came through again. Thanks to treatments from psoriasis-fighter Stelara to antipsychotic Invega Sustenna, the company's pharma sales were up a whopping 25% in the U.S. for 2014, and 15% worldwide, to $32.4 billion.

J&J, IOM provide big boosts to data transparency agenda

The clinical trial data transparency movement was propelled forward by two major developments this week. On the same day, influential national academy the Institute of Medicine called for more systematic sharing of trial results and Johnson & Johnson agreed to extend its transparency initiative to include medical devices and diagnostics.

Philips to provide data on 100,000+ ICU patients to researchers via collaboration with MIT

Philips announced that it will share anonymized data on more than 100,000 patients collected via its Hospital to Home eICU telehealth initiative with the Massachusetts Institute of Technology. 

J&J gets $116M to help hustle along new Ebola vaccine

Just days after Johnson & Johnson began a Phase I study of its new Ebola vaccine the pharma giant has organized an alliance to help accelerate its work and picked up a $116 million-plus grant to add to its $200 million commitment to get the job done as quickly as possible.

Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue

Earlier this week, once-skeptical Johnson & Johnson CEO Alex Gorsky seemed to be fully on-board pharma's slim-down bandwagon, telling presentation-watchers at the JP Morgan Healthcare Conference he was willing to jettison pieces of the J&J puzzle if they didn't present a "path to achieving leadership." Now, he's followed up with another divestment that will send U.S. rights to pain med Nucynta to California's Depomed.